Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: Pooled analysis of data from phase 3 and 4 clinical trials

Rheumatology (United Kingdom)

Volumn 56, Issue 4, 2017, Pages 541-549

  Moots, Robert J ^a   Sebba, Anthony ^b   Rigby, William ^c   Ostor, Andrew ^d   Porter Brown, Benjamin ^e   Donaldson, Francis ^e   Dimonaco, Sophie ^e   Rubbert Roth, Andrea ^f   van Vollenhoven, Ronald ^g   Genovese, Mark C ^h  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

^d ADDENBROOKE S HOSPITAL   (United Kingdom)

^e ROCHE PRODUCTS LTD   (United Kingdom)

^f UNIVERSITY OF COLOGNE   (Germany)

^g KAROLINSKA INSTITUTE   (Sweden)

^h STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Biological therapies; Infections and arthritis; Inflammation; Neutrophils; Rheumatoid arthritis

Indexed keywords

METHOTREXATE; TOCILIZUMAB; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG EXPOSURE; FEMALE; HUMAN; INCIDENCE; INFECTION; INFECTION RATE; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; NEUTROPHIL; NEUTROPHIL COUNT; PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SEX DIFFERENCE; SIDE EFFECT; ARTHRITIS, RHEUMATOID; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; LEUKOCYTE ACTIVATION; LEUKOCYTE COUNT; META ANALYSIS; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS, PHASE III AS TOPIC; CLINICAL TRIALS, PHASE IV AS TOPIC; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; NEUTROPHIL ACTIVATION; NEUTROPHILS; OPPORTUNISTIC INFECTIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85017264825     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kew370     Document Type: Article

References (32)

1. Wright HL, Moots RJ, Edwards SW. The multifactorial role of neutrophils in rheumatoid arthritis. Nat Rev Rheumatol 2014;10:593-601.
2. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro-and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta 2011;1813:878-88.
3. Gabay C. Interleukin-6 and chronic inflammation. Arthritis Res Ther 2006;8(Suppl 2):S3.
4. Chalaris A, Rabe B, Paliga K et al. Apoptosis is a natural stimulus of IL6R shedding and contributes to the proinflammatory trans-signaling function of neutrophils. Blood 2007;110:1748-55.
5. Ottonello L, Frumento G, Arduino N et al. Differential regulation of spontaneous and immune complex-induced neutrophil apoptosis by proinflammatory cytokines: role of oxidants, Bax and caspase-3. J Leukoc Biol 2002;72:125-32.
6. McNamee JP, Bellier PV, Kutzner BC, Wilkins RC. Effect of pro-inflammatory cytokines on spontaneous apoptosis in leukocyte sub-sets within a whole blood culture. Cytokine 2005;31:161-7.
7. Wright HL, Cross AL, Edwards SW, Moots RJ. Effects of IL-6 and IL-6 blockade on neutrophil function in vitro and in vivo. Rheumatology 2014;53:1321-31.
8. Suwa T, Hogg JC, English D, van Eeden SF. Interleukin-6 induces demargination of intravascular neutrophils and shortens their transit in marrow. Am J Physiol Heart Circ Physiol 2000;279:H2954-60.
9. Hashizume M, Higuchi Y, Uchiyama Y, Mihara M. IL-6 plays an essential role in neutrophilia under inflammation. Cytokine 2011;54:92-9.
10. Daniel D, Crawford J. Myelotoxicity from chemotherapy. Semin Oncol 2006;33:74-85.
11. Mihara M, Kasutani K, Okazaki M et al. Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol 2005;5:1731-40.
12. Nishimoto N, Terao K, Mima T et al. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 2008;112:3959-64.
13. SchiffMH, Kremer JM, Jahreis A et al. Integrated safety in tocilizumab clinical trials. Arthritis Res Ther 2011;13:1-13.
14. Gabay C, Emery P, van Vollenhoven R et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 2013;381:1541-50.
15. Smolen JS, Beaulieu A, Rubbert-Roth A et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a doubleblind, placebo-controlled, randomised trial. Lancet 2008;371:987-97.
16. Genovese MC, McKay JD, Nasonov EL et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008;58:2968-80.
17. Emery P, Keystone E, Tony HP et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516-23.
18. Jones G, Sebba A, Gu J et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010;69:88-96.
19. Kremer JM, Blanco R, Brzosko S et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum 2011;63:609-21.
20. Genovese MC, Rubbert-Roth A, Smolen JS et al. Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure. J Rheumatol 2013;40:768-80.
21. National Cancer Institute. Cancer Therapy Evaluation Program: Common Terminology Criteria for Adverse Events V3.0 (CTCAE). Bethesda, MD: National Cancer Institute; 2006. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf. (14 October 2015, date last accessed).
22. ACTEMRA®(tocilizumab) injection, for intravenous use injection, for subcutaneous use [prescribing information]. South San Francisco, CA: Genentech, Inc., 2014.
23. RoActemra 20 mg/ml concentrate for solution for infusion [prescribing information]. Welwyn Garden City, UK: Roche Registration Ltd, 2014.
24. Kivitz A, Olech E, Borofsky M et al. Subcutaneous tocilizumab versus placebo in combination with diseasemodifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Care Rese 2014;66:1653-61.
25. Burmester GR, Rubbert-Roth A, Cantagrel A et al. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann Rheum Dis 2014;73:69-74.
26. Listing J, Strangfeld A, Kary S et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005;52:3403-12.
27. Askling J, Fored CM, Brandt L et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 2007;66:1339-44.
28. Galloway JB, Hyrich KL, Mercer LK et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology 2011;50:124-31.
29. Curtis JR, Xie F, Chen L et al. The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents. Ann Rheum Dis 2011;70:1401-6.
30. European Medicines Agency. Assessment Report for RoActemra. http://www.ema.europa.eu/ema/index.jsp?curl=search.jsp&q=Doc. Ref.%3A+EMEA%2F26276 %2F2009&btnG=Search&mid= (14 October 2015, date last accessed).
31. Hastings R, Ding T, Butt S et al. Neutropenia in patients receiving anti-tumor necrosis factor therapy. Arthritis Care Res 2010;62:764-9.
32. Jawaheer D, Messing S, Reed G et al. Significance of sex in achieving sustained remission in the consortium of rheumatology researchers of North America cohort of rheumatoid arthritis patients. Arthritis Care Res 2012;64:1811-8.